high dose oral semaglutide Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) FDA Approves Oral Semaglutide: First

The gradual approach allows the body to adapt to the amylin receptor activation, and clinical trial data shows that nausea rates drop substantially with proper dose escalation

Weight neutral or modest weight loss in most obese or diabetic patients (Table 1)

Epub 2020 May 26

If youd rather not offer organ meats as a source of vitamin E or you have too much organ meat in their diet already (shouldnt exceed more than 3-5% of their overall diet), you can also provide salmon, trout, or herring as a source

Wegovy is popular brand of weight loss medicine

Data sources for all outcomes have listed in Additional file 1: Table S1